Royce & Associates’s Heron Therapeutics HRTX Stock Holding History

Royce & Associates’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-72,600	Closed	-$852K	–	1186
2020 Q1	$852K	Hold	72,600	–	–	0.01%	759
2019 Q4	$1.71M	Buy	72,600 +2,600	+4%	+$57.5K	0.02%	728
2019 Q3	$1.29M	Hold	70,000	–	–	0.01%	771
2019 Q2	$1.3M	Hold	70,000	–	–	0.01%	806
2019 Q1	$1.71M	Hold	70,000	–	–	0.01%	778
2018 Q4	$1.82M	Buy	70,000 +5,000	+8%	+$137K	0.02%	760
2018 Q3	$2.06M	Hold	65,000	–	–	0.01%	818
2018 Q2	$2.52M	Sell	65,000 -17,500	-21%	-$557K	0.02%	774
2018 Q1	$2.28M	Hold	82,500	–	–	0.02%	811
2017 Q4	$1.49M	Buy	82,500 +15,000	+22%	+$245K	0.01%	900
2017 Q3	$1.09M	Buy	67,500 +10,000	+17%	+$157K	0.01%	938
2017 Q2	$796K	Buy	+57,500	New	+$833K	0.01%	1006
2015 Q2	–	Sell	-59,147	Closed	-$861K	–	1226
2015 Q1	$861K	Sell	59,147 -111,433	-65%	-$1.26M	﹤0.01%	1042
2014 Q4	$1.72M	Buy	+170,580	New	+$1.39M	0.01%	997

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royce & Associates's HRTX Position: Q2 2020 in Review

Royce & Associates sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 72,600 shares — an estimated $852K sold.

Royce & Associates first reported a position in HRTX in Q4 2014 and held it in 14 quarters. The position peaked at $2.52M in Q2 2018. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

Royce & Associates reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
Royce & Associates sold 72,600 Heron Therapeutics shares in Q2 2020, an estimated $852K.
Royce & Associates first reported a position in Heron Therapeutics in Q4 2014 and held it in 14 quarters.
Royce & Associates's Heron Therapeutics position peaked at $2.52M in Q2 2018.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on Royce & Associates's 13F filing for Q2 2020, filed 7 Aug 2020.